Share

March 2018; 5 (2) ArticleOpen Access

Proinflammatory B-cell profile in the early phases of MS predicts an active disease

Thomas Guerrier, Myriam Labalette, David Launay, Catalina Lee-Chang, Olivier Outteryck, Guillaume Lefèvre, Patrick Vermersch, Sylvain Dubucquoi, Hélène Zéphir
First published December 26, 2017, DOI: https://doi.org/10.1212/NXI.0000000000000431
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
1101

Share

Article Information

vol. 5 no. 2 e431
DOI: 
https://doi.org/10.1212/NXI.0000000000000431
PubMed: 
29296635
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received August 21, 2017
  • Accepted in final form October 30, 2017
  • First Published December 26, 2017.
Copyright & Usage: 
Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Thomas Guerrier, PhD,
    2. Myriam Labalette, MD, PhD,
    3. David Launay, MD, PhD,
    4. Catalina Lee-Chang, PhD,
    5. Olivier Outteryck, MD, PhD,
    6. Guillaume Lefèvre, MD, PhD,
    7. Patrick Vermersch, MD, PhD,
    8. Sylvain Dubucquoi, MD, PhD* and
    9. Hélène Zéphir, MD, PhD*
  1. Thomas Guerrier, PhD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1)GENZYME

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. (1)Universit? Lille 2

    Research Support, Foundations and Societies:

    1. (1)Fondation pour la Recherche (2)ARSEP

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Myriam Labalette, MD, PhD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. David Launay, MD, PhD,
    4. Scientific Advisory Boards:

    1. Shire

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Shire, GSK, CSL Behring, Pfizer

    Editorial Boards:

    1. Revue de M?decine Interne, associate editor, 2002-ongoing

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Catalina Lee-Chang, PhD,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Olivier Outteryck, MD, PhD,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Bayer Schering Pharma, funding for travel and speaker honoraria; (2) Biogen Idec, funding for travel and speaker honoraria; (3) Merck Serono, funding for travel; (4) Novartis, funding for travel and speaker honoraria (5) Sanofi-Aventis, funding for travel and speaker honoraria; (6) Teva Pharmaceutical Industries Ltd, funding for travel

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1)research grants from Biogen Idec and Novartis

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Guillaume Lefèvre, MD, PhD,
    7. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Patrick Vermersch, MD, PhD,
    8. Scientific Advisory Boards:

    1. Serves on scientific advisory boards for (1) Sanofi, (2) Biogen, (3) Merck, (4) Teva, (5) Novartis, (6) Roche, (7) Servier, (8) Celgene

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Biogen, travel and speaker honoraria; (2) Roche, travel and honoraria; (3) Novartis, honoraria; (4) Teva, travel and honoraria; (5) Sanofi-Aventis, honoraria; (6) Almirall, honoraria (6) Merck Serono, travel and honoraria (7) Celgene, travel and honoraria

    Editorial Boards:

    1. Neurosciences et scl?rose en plaques

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Research support from (1) Biogen, (2) Novartis, (3) Merck, (4) Sanofi-Genzyme, (5) Roche

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Sylvain Dubucquoi, MD, PhD* and
    9. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  9. Hélène Zéphir, MD, PhD*
    10. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. I received consultancies fees from BIOGENIDEC, MERCK, BAYER, NOVARTIS, SANOFI, GENZYME, TEVA

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. I received research support grants from TEVA

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. I received research support grants from Ligue Fran?aise contre la scl?rose en plaques and from ARSEP (Association de recherche contre la Scl?rose en plaques)

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Université de Lille, CHU Lille, LIRIC-INSERM U 995, FHU Imminent, France.
  1. Correspondence to Dr. Zéphir: helene.zephir{at}chru-lille.fr

Article usage

Article usage: December 2017 to October 2023

AbstractFullPdfSource
Dec 2017037936Highwire
Jan 20180887149Highwire
Feb 2018019848Highwire
Mar 2018197376Highwire
Apr 2018028624Highwire
Apr 2018223541pmc
May 2018022410Highwire
Jun 2018013917Highwire
Jun 2018222935pmc
Jul 2018010710Highwire
Aug 201814214Highwire
Aug 201841516pmc
Sep 2018016113Highwire
Oct 2018023713Highwire
Nov 2018027012Highwire
Dec 201803668Highwire
Jan 2019126913Highwire
Feb 201982076Highwire
Mar 2019411420Highwire
Apr 201931227Highwire
May 2019610210Highwire
Jun 20196727Highwire
Jul 2019414011Highwire
Aug 201922319Highwire
Sep 201912126Highwire
Oct 201962296Highwire
Nov 2019317110Highwire
Dec 2019413410Highwire
Jan 20201575Highwire
Feb 20201257Highwire
Mar 202052615Highwire
Apr 202005311Highwire
May 20200869Highwire
Jun 20201578Highwire
Jul 20200694Highwire
Aug 20200333Highwire
Sep 202053710Highwire
Oct 20200419Highwire
Nov 202015415Highwire
Dec 20203428Highwire
Jan 202122817Highwire
Feb 202101610Highwire
Mar 202142113Highwire
Apr 202127810Highwire
May 20211204Highwire
Jun 20215238Highwire
Jul 202112810Highwire
Aug 20212465Highwire
Sep 202113410Highwire
Oct 202142724Highwire
Nov 202135018Highwire
Dec 20213305Highwire
Jan 20223168Highwire
Feb 20221178Highwire
Mar 20222149Highwire
Apr 20220227Highwire
May 202222616Highwire
Jun 20226169Highwire
Jul 202231210Highwire
Aug 20226245Highwire
Sep 202232918Highwire
Oct 20224329Highwire
Nov 202276324Highwire
Dec 202212612Highwire
Jan 20234378Highwire
Feb 20232208Highwire
Mar 202321512Highwire
Apr 20232145Highwire
May 202361411Highwire
Jun 2023275Highwire
Jul 2023111014Highwire
Aug 20231914Highwire
Sep 20233116Highwire
Oct 20232118Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. [email protected]
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Topics Discussed

Alert Me

Recommended articles